AlbaJuna Therapeutics, SL

AlbaJuna Therapeutics, SL

Constitution date: 13/01/2016 Researchers: Bonaventura Clotet, Jorge Carrillo, Julià Blanco

AlbaJuna Therapeutics,

AlbaJuna Therapeutics is the result of the agreement between IrsiCaixa, Grifols corporation and the researchers Bonaventura Clotet, Jorge Carrillo and Julià Blanco.  The spin-off is  developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the “natural killer” cells responsible for destroying cells infected by the virus.

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

Obra Social - Fundació 'La Caixa' Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

In cooperation with: